Invasion and destruction of a murine fibrosarcoma by Salmonella-induced effector CD8 T cells as a therapeutic intervention against cancer

Cancer Immunology, Immunotherapy

Volumn 60, Issue 3, 2011, Pages 371-380

  Roider, Elisabeth ^a   Jellbauer, Stefan ^a   Köhn, Brigitte ^a   Berchtold, Christina ^a   Partilla, Miriam ^a   Busch, Dirk H ^b,c   Rüssmann, Holger ^d   Panthel, Klaus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d Institute for Microbiology Immunology and Laboratory Medicine   (Germany)

Author keywords

Murine fibrosarcoma model; Salmonella vaccine; Therapeutic anti tumor immunity; Tumor invading effector CD8 T cells

Indexed keywords

INTERLEUKIN 7 RECEPTOR; L SELECTIN; PROTEIN P60; SALMONELLOSIS VACCINE; BACTERIAL PROTEIN; CANCER VACCINE; LIPOPROTEIN; P60 PROTEIN, BACTERIA; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CANCER GROWTH; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FIBROSARCOMA; IMMUNOGENICITY; MEMORY CELL; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; SALMONELLA; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME; TYPE III SECRETION SYSTEM; ANIMAL; BAGG ALBINO MOUSE; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE MODEL; FEMALE; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; SALMONELLA TYPHIMURIUM; TUMOR CELL LINE;

ANIMALS; BACTERIAL PROTEINS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; FIBROSARCOMA; GENETIC VECTORS; IMMUNOTHERAPY; LIPOPROTEINS; MICE; MICE, INBRED BALB C; RECOMBINANT PROTEINS; SALMONELLA TYPHIMURIUM;

EID: 79953826863     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0950-x     Document Type: Article

References (43)

1. Berchtold C, Panthel K, Jellbauer S, Köhn B, Roider E, Partilla M, Heesemann J, Endres S, Bourquin C, Rüssmann H (2009) Superior protective immunity against murine listeriosis by combined vaccination with CpG DNA and recombinant Salmonella. Infect Immun 77:5501-5508
2. Busch DH, Pilip I, Pamer EG (1998) Evolution of a complex TCR repertoire during primary and recall bacterial infection. J Exp Med 188:61-70
3. Busch DH, Pilip IM, Vijh S, Pamer EG (1998) Coordinate regulation of complex T cell populations responding to bacterial infection. Immunity 8:353-362
4. Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303-1310
5. Coley WB (1893) The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. Clin Orthop Relat Res 262:3-11
6. Diederichsen AC,Hjelmborg JB, Christensen PB, Zeuthen J, Fenger C (2003) Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 52:423-428
7. Dougan G (1994) The molecular basis for the virulence of bacterial pathogens: implications for oral vaccine development. Microbiology 140:215-224
8. Galán JE (2001) Salmonella interactions with host cells: type III secretion at work. Annu Rev Cell Dev Biol 17:53-86
9. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL (1993) Natural history of HLA expression during tumour development. Immunol Today 10:491-499
10. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M, Stern PL (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 18:89-95
11. Goedegebuure PS, Eberlein TJ (1995) The role of CD4+ tumorinfiltrating lymphocytes in human solid tumors. Immunol Res 14:119-131
12. Guard-Petter J (1998) Variants of smooth Salmonella enterica serovar Enteritidis that grow to higher cell density than the wild type are more virulent. Appl Environ Microbiol 6:2166-2172
13. Guttinger M, Guidi F, Chinol M, Reali E, Veglia F, Viale G, Paganelli G, Corti A, Siccardi AG (2000) Adoptive immunotherapy by avidin-driven cytotoxic T lymphocyte-tumor bridging. Cancer Res 60:4211-4215
14. Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM (2000) Eradication of established tumors by CD8+ T cells adoptive immunotherapy. Immunity 13:265-276
15. + memory T cell subsets. Proc Natl Acad Sci USA 101:5610-5615
16. + central memory T cells into protective Listeria-specific effector memory T cells. Eur J Immunol 36:1453-1464
17. Kotton CN, Hohmann EL (2004) Enteric pathogens as vaccine vectors for foreign antigen delivery. Infect Immun 72:5535-5547
18. Lizée G, Cantu MA, Hwu P (2007) Less yin, more yang: confronting the barriers to cancer immunotherapy. Clin Cancer Res 13:5250-5255
19. Marzo AL, Lake RA, Robinson BW, Scott B (1999) T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 59:1071-1079
20. Masopust D, Vezys V, Marzo AL, Lefrancois L (2001) Preferential localization of effector memory cells in non-lymphoid tissue. Science 291:2413-2417
21. Medina E, Guzmán CA (2001) Use of bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 19:1573-1580
22. Minev BB, Mc Farland BJ, Spiess OJ, Rosenberg SA, Restifo NP (1994) Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice. Cancer Res 54:4155-4161
23. Monsurro V, Wang E, Panelli MC, Nagorsen D, Jin P, Katia Z, Smith K, Ngalame Y, Even J, Marincola FM (2003) Activespecific immunization against melanoma: is the problem at the receiving end? Semin Cancer Biol 13:473-480
24. Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:180-183
25. Morse MA, Chui S, Hobeika A, Lyerly HK, Clay T (2004) Recent developments in therapeutic cancer vaccines. Nat Clin Pract Oncol 2:108-113
26. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58:3491-3494
27. Panthel K, Meinel KM, Sevil Domenech VE, Geginat G, Linkemann K, Busch DH, Rüssmann H (2006) Prophylactic antitumor immunity against a murine fibrosarcoma triggered by the Salmonella type III secretion system. Microbes Infect 8:2539-2546
28. Panthel K, Meinel KM, Sevil Domènech VE, Trülzsch K, Rüssmann H (2008) Salmonella type III-mediated antigen delivery: a versatile oral vaccination strategy to induce cellular immunity against infectious agents and tumors. Int J Med Microbiol 298:99-103
29. Prall F, Dührkop T, Weirich V, Ostwald C, Lenz P, Nizze H, Barten M (2004) Prognostic role of CD8+ tumor-infiltrating lymphocytes in stage III colorectal cancer with and without microsatellite instability. Hum Pathol 35:808-816
30. Proskuryakov SY, Gabai VL (2010) Mechanisms of tumor cell necrosis. Curr Pharm Des 16:56-68
31. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909-915
32. Rüssmann H, Shams H, Poblete F, Fu Y, Galán JE, Donis RO (1998) Delivery of epitopes by the Salmonella type III secretion system for vaccine development. Science 281:565-568
33. Rüssmann H, Igwe EI, Sauer J, Hardt WD, Bubert A, Geginat G (2001) Protection against murine listeriosis by oral vaccination with recombinant Salmonella expressing hybrid Yersinia type III proteins. J Immunol 167:357-365
34. Rüssmann H (2003) Bacterial type III translocation: a unique mechanism for cytosolic display of heterologous antigens by attenuated Salmonella. Int J Med Microbiol 293:107-112
35. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538-18543
36. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401:708-712
37. Seliger B, Maeurer MJ, Ferrone S (1997) TAP off-tumors on. Immunol Today 18:292-299
38. Slingluff CL Jr, Speiser DE (2005) Progress and controversies in developing cancer vaccines. J Transl Med 3:18
39. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H (1998) Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc Natl Acad Sci USA 95:1178-1183
40. Walker EB, Disis ML (2003) Monitoring immune responses in cancer patients receiving tumor vaccines. Int Rev Immunol 22:283-319
41. Whiteside TL (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16:3-15
42. Wright SD, Ramos RA, Patel M, Miller DS (1992) Septin: a factor in plasma that opsonizes lipopolysaccharide-bearing particles for recognition by CD14 on phagocytes. J Exp Med 176:719-727
43. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213